Impact of Statin Treatment on the Clinical Fate of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
AIM: Familial hypercholesterolemia (FH) patients are at particular risk for premature coronary artery disease (CAD) caused by high levels of low density lipoprotein (LDL). Administration of statins enabled us to reduce LDL-C levels in heterozygous FH patients. To evaluate the impact of statins on the clinical fate of heterozygous FH, a retrospective study was performed. METHODS: We analyzed the clinical influence of statins on age at the first clinical onset of CAD in 329 consecutive FH patients referred to the lipid clinic of the National Cardiovascular Center. Among 329 heterozygous FH patients, the onset of CAD was identified in 101. RESULTS: The age at onset of CAD was 58.8+/-12.5 years in the 25 patients on statins at onset, significantly higher than that in the 76 patients not on statins (47.6+/-10.5 years) (p <0.001). The average age at CAD onset was significantly higher after widespread use of statins (54.2+/-13.2 years in 48 patients, Group 1) compared to before October 1989 when statins were approved in Japan (46.9+/-9.6 years in 53 patients; Group 2, p=0.002). A significant difference was seen between Groups 1 and 2 in the variables, including sex, prevalence of smoking habit, LDL-C, and the use of statins, aspirin and probucol. After adjusting for these variables, only statin use was independently associated with the difference in age at CAD onset by multivariable analysis. CONCLUSION: Statins have improved the clinical course of patients with heterozygous FH.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cumulative LDL-C from birth plays a role in cardiovascular incidence.
“It has been reported that the cumulative LDL-C (total LDL-C from the time of birth) plays a role in cardiovascular incidence732).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [732]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 29 · Cited by 70
Research works printed but not linked: 3
- Goldstein JL HH, Brown MS, Familial hypercholesterol- emia, New York, McGraw-Hill, 2001: 2863-2913
- Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neu- wirth C, Rendell NB, Taylor GW, Thompson GR: Pro- longed inhibition of cholesterol synthesis explains the effi- cacy of atorvastatin. J Lipid Res, 1997; 38: 1496-1500
- Mabuchi H, Koizumi J, Shimizu M, Takeda R: Develop- ment of coronary heart disease in familial hypercholester- olemia. Circulation, 1989; 79: 225-232
- Authors
- Harada-Shiba, M., Sugisawa, T., Makino, H., Abe, M., Tsushima, M., Yoshimasa, Y., Yamashita, T., Miyamoto, Y., Yamamoto, A., Tomoike, H., & Yokoyama, S.
- Affiliations
- Nagoya City University (JP)
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2010
- Volume
- 17
- Issue
- 7
- Pages
- 667-674
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- OpenAlex
- W2070058926
- Cited by
- 70
- References
- 29
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 4 · 2017: 6 · 2016: 10 · 2015: 1 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- heterozygous familial hypercholesterolemia, statins, coronary artery disease, age of onset, LDL cholesterol, statin therapy, smoking, aspirin, probucol, lipid-lowering therapy
- MeSH terms
- Adult, Aged, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Japan, Lipids, Male, Middle Aged, Retrospective Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
